Clinical Trial Update: Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating dose optimization of infliximab in adults with moderate-to-severe plaque psoriasis was terminated; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Psoriasis | Phase 3 | Status: TERMINATED | Results posted: 2012-07-26